Vascular Biogenics
Vascular Biogenics, a company developing biologics for cancer and immune-inflammatory diseases, has scheduled a $76m IPO on the NASDAQ.
Existing shareholders have indicated an interest in buying $35 million on the IPO.
Vascular Biogenics (“VBLX”) has a pipeline based on two separate platforms: one oncology-focused, another anti-inflammatory-focused.
Its lead oncology candidate, VB-111, is a gene-based biologic aimed at recurrent glioblastoma, (rGBM), an aggressive form of brain cancer. The candidate has received US FDA fast track designation.
The company has stated it intends to use $30m of its IPO proceeds to fund clinical development of VB-111.
(Pictured: a human T-cell. Credit: Flickr/NIAID)
